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Implantation-Related Complications
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and Cardiac Resynchronization Therapy Devices
A Systematic Review of Randomized Clinical Trials
Johannes B. van Rees, MD, Miha´ly K. de Bie, MD, Joep Thijssen, MD,
C. Jan Willem Borleffs, MD, PHD, Martin J. Schalij, MD, PHD, Lieselot van Erven, MD, PHD
Leiden, the Netherlands
The number of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT) implantations
is increasing drastically worldwide, and hence, the number of implanting centers is also increasing. Despite abundant
data on the beneficial effect of these devices, little is known regarding safety and complication rates. Eleven ICD and
7 CRT trials were systematically reviewed to provide data on the frequency of in-hospital mortality and complications
related to the implantation. Average in-hospital mortality was 2.7% in trials using both thoracotomy and nonthora-
cotomy ICDs, 0.2% in trials using nonthoracotomy ICDs, and 0.3% in CRT trials. The pneumothorax rate was similar
between the nonthoracotomy ICD and CRT trials (0.9%) Coronary sinus complications occurred in 2.0% of patients
undergoing CRT. Lead dislodgement rates were higher in CRT trials (5.7%) than in nonthoracotomy ICD trials
(1.8%). (J Am Coll Cardiol 2011;58:995–1000) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.007Inclusion of implantable cardioverter-defibrillator (ICD)
treatment and cardiac resynchronization therapy (CRT) in
the guidelines has led to a worldwide drastic increase in
implantation rates (1). Most likely this rate will continue to
rise in the future, given the growing number of eligible
patients, expanding indications, and existing backlog of
device implantations (1–3). Nevertheless, despite improved
training, advancing techniques, and better experience, de-
vice implantation is not without complications.
Given the expected growing number of device implanta-
tions, data on the safety of the implant procedure are necessary
to create reasonable expectations of procedural risk and guid-
ance for (starting) implanting centers. The objective of this
review is to assess the frequency of implantation-related com-
plications reported in large, randomized clinical trials—which
are under strict control of safety boards—and provide guidance
for implanting centers and safety enhancement.
Methods
Literature review. A comprehensive search of English-
anguage published reports was conducted in PubMed on
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accepted June 7, 2011.the following search terms: implantable cardioverter defi-
brillator, cardiac resynchronization therapy, and biventricu-
lar pacing. The search was conducted on October 15, 2010,
and was limited to clinical trials. Two independent review-
ers (J.B.v.R. and M.K.d.B.) screened and selected the
studies. A preliminary screening of titles and abstracts was
conducted, and those with potential relevance were re-
trieved. Disagreements were resolved by consensus or by a
third reviewer (L.v.E.).
Selection criteria. Eligible studies were noncrossover ran-
domized clinical trials examining patients undergoing elec-
tive ICD or CRT versus controls and reporting on compli-
cations or adverse events related to the implant procedure.
Data on adverse events from subgroup analyses of these
trials were also included. Of 1,026 results for the search
term implantable cardioverter defibrillator, 388 results for
cardiac resynchronization therapy, and 201 results for
biventricular pacing, 18 trials and 3 subgroup analyses were
selected for this review (4–24) (Fig. 1).
The included trials were separated into 3 groups based on
the devices used: both thoracotomy and nonthoracotomy
ICDs, only nonthoracotomy ICDs, and nonthoracotomy
CRTs. The AVID (Antiarrhythmics Versus Implantable
Defibrillators) trial—using mainly nonthoracotomy ICDs
(93%)—was included in the nonthoracotomy ICD group
because Kron et al. (12,22) provided accurate data in a
subgroup analysis that included only nonthoracotomy
ICDs.
996 van Rees et al. JACC Vol. 58, No. 10, 2011
ICD and CRT Implantation-Related Complications August 30, 2011:995–1000Results
Included studies. Twelve trials
assessing ICD efficacy were se-
lected, including the ICD-treated
arm of the MADIT-CRT (Mul-
ticenter Automatic Defibrillator
Implantation Trial–Cardiac Re-
synchronization Therapy) study. Year of publication ranged
from 1996 to 2009 (4–14,21). Of these, 4 trials used both
thoracotomy and nonthoracotomy ICDs, which resulted in
successful implantation in 932 of 951 patients (98.0%)
(4,5,13,14). In the remaining 8 nonthoracotomy ICD trials,
implantation was successful in 3,787 of 3,828 patients
(98.9%).
Significantly lower successful implantation rates were
observed in the 7 selected CRT trials: 4,175 of 4,512
(92.5%) attempted implantations were successful (15–21).
In Table 1, an overview of the trials with key baseline
clinical characteristics is presented.
Mortality. Average in-hospital mortality of the trials using
both thoracotomy and nonthoracotomy ICDs was 2.7%
(Table 2). Nonthoracotomy ICD trials reported signifi-
cantly lower rates: of 3,016 patients, 5 patients died in-
hospital (0.2%) and 13 patients within 30 days (0.6%).
Importantly, all in-hospital deaths happened during the
IRIS (Immediate Risk Stratification Improves Survival)
trial, which disproved that ICDs provide survival benefit
when implanted within 40 days following myocardial in-
farction (11). Hence, this study population consisted of
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
ICD  implantable
cardioverter-defibrillator
Figure 1 Systematic Review and Article Selection
Flow chart demonstrating the search strategy and exclusion of articles.patients at high risk of death, explaining the high in-
hospital mortality.
Interestingly, in a large registry including patients with
heart failure undergoing ICD implantation in 2004 and
2005, Swindle et al. (25) reported a relatively high in-
hospital mortality of 1.0%, and comparable findings were
reported by Reynolds et al. (26) in Medicare patients
(0.9%). Most likely, the strict inclusion criteria of the
trials—creating a more healthy population—and the expe-
rience of the implanting centers have led to this in-hospital
mortality rate difference in favor of the trials.
For CRT patients, the average in-hospital mortality was
0.3% and mortality within 30 days was 0.7%. Given these
findings, it seems that in-hospital mortality was not affected
by the more complex and time-consuming CRT implant
procedures, conducted in generally sicker patients. This was
also observed by Reynolds et al. (26) in 30,984 Medicare
patients: in-hospital mortality for CRT patients (1.1%) was
comparable to that for ICD patients (0.9%; p  0.07).
Complications during implantation. PNEUMOTHORAX. For
implanting nonthoracotomy ICD or CRT leads, venous
access can be achieved via the cephalic, subclavian, or
axillary vein. Of these, the blind puncture approach of the
subclavian vein is most associated with the risk of a
pneumothorax (27). The selected trials did not specifically
report on the implantation technique used; however, for
patients receiving nonthoracotomy devices, the incidence of
pneumothorax was relatively low: a pneumothorax was
observed in 14 of 1,497 ICD implantations (0.9%) and in 30
Baseline Characteristics of the Included StudiesTable 1 Baseline Characteristics of the Included Studies
First/Author Trial (Ref. #) Year
Device 
Procedure
Thoracotomy
ICD, % Patients, n
Attempted
First
Procedures, n
Successful
Implants,
n (%)*
Mean Age,
yrs
Male,
n (%)
Mean
LVEF, %
Ischemic
Heart
Disease,
n (%)
NYHA II or III,
n (%)
NYHA IV,
n (%)
Duration,
months
Thoracotomy and nonthoracotomy ICD systems
Moss et al. MADIT (4) 1996 ICD 47 95 95 94 (99) 62 9 87 (92) 27 7 95 (100) 60 (63) Excluded 27
Bigger, Jr et al. CABG Patch (5) 1997 ICD CABG 100 446 446 434 (97) 64 9 386 (87) 27 6 446 (100) 317 (71) NR 32 16
Connolly et al. CIDS (13) 2000 ICD 10 328 311 310 (99) 63 9 280 (85) 34 15 272 (83) NR NR 36
Kuck et al. CASH (14) 2000 ICD 56 99 99 94 (95) 58 11 78 (79) 46 19 72 (73) 76 (77) 0 (0) 57 34
Nonthoracotomy ICD systems
AVID
investigators
AVID (12,22) 1997 ICD 0 539 539 539 (100) 65 11 424 (79) 32 13 438 (81) NR NR 27 13
Moss et al. MADIT II (6) 2002 ICD 0 742 742 721 (97) 64 10 631 (85) 23 5 742 (100) 379 (60) 37 (5) 20
Bansch et al. CAT (7) 2002 ICD 0 50 50 50 (100) 52 12 43 (86) 24 6 Excluded 50 (100) Excluded 25
Hohnloser et al. DINAMIT (8) 2004 ICD 0 332 312 312 (100) 62 11 252 (76) 28 5 332 (100) III: 100 (30) Excluded 30 13
Kadish et al. DEFINITE (9) 2004 ICD 0 229 227 227 (100) 58 (21–78) 160 (70) 22 (7–35) Excluded 171 (75) Excluded 29 14
Bardy et al. SCD-HeFT (10) 2005 ICD 0 829 812 811 (99) 60, median 639 (77) 24, median 431 (53) 829 (100) Excluded 46
Moss et al. MADIT-CRT (21) 2009 ICD arm 0 731 731 712 (97) 64 11 553 (76) 24 5 401 (55) II: 618 (85) Excluded 29
Steinbeck et al. IRIS (11) 2009 ICD 0 445 415 415 (100) 63 11 345 (78) 35 9 445 (100) NR NR 37
Nonthoracotomy CRT systems
Abraham et al. MIRACLE (15,24) 2002 CRT 0 571 568 526 (92) 64 11 308 (68) 22 6 245 (54) III: 412 (91) 41 (9) 6
Young et al. MIRACLE ICD (16,24) 2003 CRT 0 429 421 379 (88) 67 283 (77) 24 6 257 (70) III: 328 (89) 41 (11) 6
Bristow et al. COMPANION (17) 2004 CRT 0 1,212 1,212 1,080 (89) 67 812 (67) 21 655 (54) III: 1054 (87) 158 (13) 16, median
Cleland et al. CARE-HF (18,23) 2005 CRT 0 409 404 390 (97) 67, median 304 (74) 25, median 165 (40) III: 386 (94) 23 (6) 29
Beshai et al. RethinQ (19) 2007 CRT 0 250 176 172 (98) 59 111 (65) 25 5 90 (52) III: 171 (99) Excluded 6
Linde et al. REVERSE (20) 2008 CRT 0 684 642 621 (97) 63 479 (79) 27 7 333 (55) II: 503 (82) Excluded 12
Moss et al. MADIT-CRT (21) 2009 CRT arm 0 1,089 1,089 1,007 (93) 65 11 814 (75) 24 5 598 (55) II: (937, 86) Excluded 29
*Successful implants of all attempted procedures.
AVID  Antiarrhythmics Versus Defibrillators; CABG  Coronary Artery Bypass Graft; CARE-HF  Cardiac Resynchronization–Heart Failure; CASH  Cardiac Arrest Study Hamburg; CAT  Cardiomyopathy Trial; CIDS  Canadian Implantable Defibrillator Study; COMPANION 
Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure; CRT  cardiac resynchronization therapy; DEFINITE  Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation; DINAMIT  Defibrillator In Acute Myocardial Infarction Trial; ICD 
implantable cardioverter-defibrillator; IRIS  Immediate Risk-Stratification Improves Survival; MADIT  Multicenter Automatic Defibrillator Implantation Trial; MADIT-CRT  Multicenter Automatic Defibrillator Trial with Cardiac Resynchronization Therapy; MIRACLE 
Multicenter In Sync Randomized Clinical Evaluation; MIRACLE-ICDMulticenter In Sync ICD Randomized Clinical Evaluation; NR not reported; NYHA New York Heart Association; RethinQ CRT in Patients with Heart Failure and Narrow QRS; SCD-HeFT Sudden Cardiac
Death in Heart Failure Trial.
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ICD and CRT Implantation-Related Complications August 30, 2011:995–1000of 3,300 CRT implantations (0.9%) (Table 3). In perspec-
tive, the Medicare registry (26) reported 1.0% for ICD
patients and 1.2% for CRT patients (p  NS), whereas
Peterson et al. (28) reported in the National Cardiovascular
Data Registry ICD Registry on 0.51% for CRT patients.
COMPLICATIONS RELATED TO THE LEFT VENTRICULAR LEAD. All
included CRT trials used CRTs with transvenously im-
planted leads. The most common complications included
coronary vein dissection (1.3%) and coronary vein perfora-
In-Hospital Mortality and Death Within 30 DaysTable 2 In-Hospital Mortality and Death Wit
Trial Year
Patients
Implan
Thoracotomy and nonthoracotomy ICD systems
MADIT 1996
CABG Patch 1997
CIDS 2000
CASH 2000
Total
Nonthoracotomy ICD systems
AVID 1997
MADIT II 2002
CAT 2002
DINAMIT 2004
DEFINITE 2004
MADIT-CRT (ICD arm) 2009
IRIS 2009
Total 3
Nonthoracotomy CRT systems
MIRACLE 2002
MIRACLE ICD 2003
COMPANION 2004 1
CARE-HF 2005
RethinQ 2007
MADIT-CRT (CRT arm) 2009 1
Total 3
Data not reported in the SCD-HeFT and REVERSE studies. *Related to
Abbreviations as in Table 1.
Pneumothorax Related toImplantati n of Non horacotomy DevicesTable 3 Pneumothorax Related toImplantation of Nonthoracotomy Devices
Trial Year
Patients Undergoing
Implantation, n
Events,
n (%)
Nonthoracotomy ICD systems
AVID 1997 539 6 (1.1)
DEFINITE 2004 227 2 (0.9)
MADIT-CRT (ICD arm) 2009 731 6 (0.8)
Total 1,497 14 (0.9)
Nonthoracotomy CRT systems
MIRACLE 2002 568 1 (0.2)
MIRACLE ICD 2003 421 3 (0.7)
CARE-HF 2005 404 2 (0.5)
RethinQ 2007 176 2 (1.1)
REVERSE 2008 642 4 (0.6)
MADIT-CRT (CRT arm) 2009 1,089 18 (1.7)
Total 3,300 30 (0.9)v
Data not reported in the CAT, MADIT II, DINAMIT, SCD-HeFT, IRIS, CIDS, and COMPANION studies.
Abbreviations as in Table 1.tion (1.3%). Of note, the earlier conducted studies reported
higher incidences of coronary vein–related complications
than the more recently conducted studies (Table 4). Possibly
the growing experience of physicians combined with the
technical progress of the left ventricular lead has contributed
to this decreasing trend in coronary vein complications.
Overall, complications related to coronary veins occurred
in 2.0%. In other published data, no large national registries
have reported on the complication rates in CRT patients
alone, but smaller analyses have reported on higher periop-
erative left ventricular lead complication rates ranging from
1.9% to 4.6% (24,29–31).
Implantation-related complications during follow-up. POCKET
EMATOMA. On average, pocket hematomas occurred in
2.2% of nonthoracotomy ICD recipients and in 2.4% of
CRT recipients (Table 5). However, in routine clinical
practice, the actual incidence of pocket hematomas is
probably higher because most trials only reported hemato-
mas requiring surgical reintervention, which was indicated in
a minority of cases (32). Although the development of pocket
hematoma is not directly life threatening and can be adequately
treated, early reintervention is associated with a 15-fold in-
creased risk of infection (33).
LEAD DISLODGEMENT. The overall incidence of lead dis-
odgement was 1.8% for nonthoracotomy ICDs. Unfortu-
ately, the rate was not specified for type of lead (atrial or
Implantation0 Days After Implantation
going
, n
In-Hospital
Mortality, n (%)
Death Within
30 Days, n (%)
0 (0.0) 0 (0.0)
12 (2.6) 24 (5.2)
NR 2 (0.6)
5 (5.1) NR
17 (2.7) 26 (3.1)
NR 6 (1.1)
0 (0.0) NR
0 (0.0) 0 (0.0)*
0 (0.0) 0 (0.0)*
0 (0.0) 0 (0.0)*
0 (0.0) 0 (0.0)*
5 (0.8)* 7 (1.7)
5 (0.2) 13 (0.6)
2 (0.4)* 2 (0.4)*
0 (0.0) 5 (1.2)
8 (0.6)* 17 (1.4)
0 (0.0) 1 (0.2)*
0 (0.0) 0 (0.0)
1 (0.1) 0 (0.0)
11 (0.3) 26 (0.7)
tation.Afterhin 3
Under
tation
95
446
311
99
951
539
742
50
312
227
731
415
,016
568
421
,212
409
176
,089
,875entricular located lead), and varying time frames during
cedure
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Nevertheless, from other published reports, one can imply
that the majority of lead dislodgements occur during hos-
pitalization because acute dislodgement rates of 0.56% for
single-chamber ICDs and 0.97% for dual-chamber ICDs
have been observed (34).
CRT trials demonstrated higher rates of lead dislodge-
ment, varying from 2.9% to 10.6%. In total, 184 (5.9%)
leads dislodged during and after 3,095 successful implanta-
tions. Although it has been suggested in published reports
that the difference in lead dislodgement between ICD and
CRT may simply be a function of having more leads
implanted, subgroup analysis of the collective MIRACLE
ICD (Multicenter In Sync Randomized Clinical Evaluation
Implantable Cardioverter Defibrillator) study demonstrated
that postoperatively disproportionally higher lead dislodge-
ment rates were observed for left ventricular leads than for
right atrial and right ventricular leads (6.8%, 1%, and 0.6%,
respectively) (24,34). This high rate reflects the limited
anatomic choices for the placement of the left ventricular
lead and challenges to obtain a stable pacing site.
Complications Related to Coronary Sinus in Recipients of a NonthoTable 4 Complications Related to Coronary Sinus in Recipients
Trial Year
Patients Undergoing
Implantation
Corona
Perfora
MIRACLE† 2002 568
MIRACLE ICD‡ 2003 421
COMPANION† 2004 1,212
CARE-HF† 2005 404
RethinQ§ 2007 176
REVERSE† 2008 642
MADIT-CRT (CRT arm)† 2009 1,089
Total 4,512
Values are n or n (%). *Also included pericardial effusion. †Complications occurred during the pro
Abbreviations as in Table 1.
Implant Site Hematoma or BleedingTable 5 Implant Site Hematoma or Bleeding
Trial Year
Successful
Implants, n
All Events,
n (%)
Duration,
months
Thoracotomy and nonthoracotomy ICD systems
MADIT* 1996 94 1 (1.1) 27
CABG Patch† 1997 434 22 (4.9) 0.5†
CASH‡ 2000 94 6 (6.1) 57 34
Total 622 29 (4.7)
Nonthoracotomy ICD systems
AVID‡ 1997 539 8 (1.5) 27 13
CAT‡ 2002 50 2 (4.0) 25
MADIT-CRT (ICD arm)‡ 2009 712 18 (2.5) 29
Total 1,301 28 (2.2)
Nonthoracotomy CRT systems
RethinQ‡ 2007 172 2 (1.2) 6
REVERSE‡ 2008 621 5 (0.8) 12
MADIT-CRT (CRT arm)‡ 2009 1,007 36 (3.3) 29
Total 1,800 43 (2.4)
Data not reported in the MADIT-II, DINAMIT, DEFINITE, SCD-HeFT, IRIS, CIDS, MIRACLE, COMPANION,
MIRACLE ICD, and CARE-HF studies. *No time frame indicated. †Complications occurred within 30
days following implantation. ‡Complications occurred during follow-up.
Abbreviations as in Table 1.Study limitations. Because of its design, this systematic
review is subject to some important limitations. No correc-
tions were made for heterogeneity among the selected trials,
for trial quality, or for publication bias. Reported compli-
cation rates are presented without confidence intervals.
Trials lacking safety data were excluded. Furthermore, clear
definitions of the complications were not always provided.
Finally, lead dislodgements develop over time, and different
follow-up durations might have influenced the rates.
Conclusions
This systematic review on the safety and complication rates
reported in major randomized ICD/CRT clinical trials pro-
vides guidance and expectations for patients and implanting
physicians. From the results, it becomes clear that trials that
used both thoracotomy and nonthoracotomy ICDs reported
significantly higher in-hospital mortality and higher complica-
tion rates. Furthermore, implantation of the left ventricular
lead was associated with the most complications.
tomy CRT Device With or Without DefibrillatorNonthoracotomy CRT Device With or Without Defibrillator
Dissection,
Tamponade
Coronary Vein
Dissection
Coronary Vein
Perforation
Coronary Vein
Tamponade*
.2) 23 (4.0) 12 (2.0) NR
.5) 15 (3.6) 4 (1.0) NR
.8) 5 (0.4) 12 (1.0) 5 (0.4)
.5) 5 (1.2) NR 2 (0.5)
.6) 1 (0.6) NR NR
.5) 3 (0.5) NR NR
.5) 5 (0.5) NR NR
.0) 57 (1.3) 28 (1.3) 7 (0.4)
. ‡Complications occurred during hospitalization. §No time frame indicated.
Lead Dislodgement During Follow-Up inNonthoracoto y Req iri Implanted DevicesTable 6 Lead Dislodgement During Follow-Up inNonthoracotomy Requiring Implanted Devices
Trial Year
Successful
Implants, n
All
Events, n
(%)
Duration,
months
Nonthoracotomy ICD systems
AVID* 1997 593 8 (1.5) 27 13
CAT† 2002 50 2 (4.0) 0.5†
DEFINITE* 2004 227 6 (2.6)‡ 29 14
Total 870 16 (1.8)
Nonthoracotomy CRT systems
MIRACLE* 2002 526 31 (5.9) 6
MIRACLE ICD§ 2003 379 11 (2.9) 6
CARE-HF† 2005 390 11 (2.8) 0.5†
RethinQ 2007 172 13 (7.6)¶ 6
REVERSE 2008 621 66 (10.6) 12
MADIT-CRT (CRT arm)† 2009 1,007 44 (4.4)# 0.5†
Total 3,095 176 (5.7)
Data not reported in the MADIT, CABG-Patch, MADIT II, DINAMIT, SCD-HeFT, MADIT-CRT (ICD-
treated arm), IRIS, and COMPANION studies. *Complications occurred during follow-up. †Compli-
cations occurred within 30 days following implantation. ‡Also included lead fracture. §Complica-
tions occurred during hospitalization. No time frame indicated. ¶Five cases (2.9%) involved the leftracoof a
ry Vein
tion or
35 (6
19 (4
22 (1
6 (1
1 (0
3 (0
5 (0
91 (2lead. #Included left ventricular lead only.
Abbreviations as in Table 1.
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